Skip to content
AnalystLens

Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2012

Filing Date
Filed March 1, 2013
Period End
December 31, 2012
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed March 1, 2013. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported total revenues of $42.3 milliona for 2012, down from $56.1 million in 2011, and a net loss of $53.6 million, compared with $19.8 million in 2011.

Revenues under collaborative agreements were $39.4 millionb, including $9.5 million recognized from the Pfizer Collaboration signed in December 2012. Product sales of Hylenex recombinant were $2.9 million. Research and development expense rose to $70.0 million and selling, general and administrative expense to $24.8 million.

The company has never been profitable and reports an accumulated deficit of approximately $298.6 millionc as of December 31, 2012. At year-end 2012, Halozyme had cash and cash equivalents of $99.9 million, versus $52.8 million a year earlier. The increase reflects an $81.5 million net proceeds public offering in February 2012 and a $30 million secured term loan drawn in December 2012 (net proceeds of $29.7 million).

The company expects total net cash burn of approximately $45 to $50 milliond for 2013 and states that its current cash is sufficient to fund operations for at least the next twelve months. It does not expect revenues to fund operations until 2014 at the earliest. The key risk in the filing is the rHuPH20 enzyme platform.

In August 2012 the FDA issued a complete response letter for Baxter's HyQ biologics license application, citing non-neutralizing antibodies to rHuPH20, and the FDA asked that patients no longer be dosed with rHuPH20 in the Baxter HyQ program. ViroPharma's subcutaneous Cinryze program was placed on temporary clinical hold and later allowed to resume.

Halozyme believes the HyQ issues will not significantly affect its proprietary and other collaboration candidates, but it cannot provide assurance of that outcome. Only three collaboration product candidates are in the regulatory approval process, and no proprietary candidates are.

Key Highlights

  1. Total revenues were $42.3 million in 2012 versus $56.1 million in 2011, while the net loss widened to $53.6 million from $19.8 million.
  2. Cash and cash equivalents rose to $99.9 million at December 31, 2012, supported by an $81.5 million net proceeds stock offering in February 2012 and a $30 million term loan drawn in December 2012.
  3. Management expects 2013 net cash burn of approximately $45 to $50 million and believes current cash will fund operations for at least the next twelve months.
  4. The FDA's complete response letter for Baxter's HyQ BLA (August 1, 2012) led to a request that patients no longer be dosed with rHuPH20 in the HyQ program, with the potential for similar concerns to be raised for other programs.
  5. Collaborations include Roche (five exclusive targets elected), Pfizer (new in December 2012, $9.5 million recognized), ViroPharma, Intrexon and Baxter, and 2012 revenue concentration was high: Roche accounted for 45% of total revenues and Baxter for 17%.
  6. Proprietary pipeline includes the more physiologic insulin program, PEGPH20 in a new randomized Phase 2 trial with gemcitabine and ABRAXANE expected to start in the first half of 2013, and HTI-501 for cellulite, with randomized Phase 2 data expected in the first half of 2013.
  7. The company has no manufacturing facility and relies on contract manufacturers Avid and Cook for bulk rHuPH20 API, and on Baxter and a third party for fill and finish of Hylenex recombinant.

Follow one dollar

For each $1.00 of revenue in FY2012, Halozyme Therapeutics lost $1.27.

  1. Revenue$42.3M100.0%
  2. Cost of revenue−$1.1M2.6%
  3. Gross profit$41.2M97.4%
  4. Operating costs−$94.9M224.1%
  5. Operating income−$53.6M126.7%
  6. Interest, other & tax$73,0000.2%
  7. Net income−$53.6M126.5%
Computed from 10-KFY2012filed March 1, 2013Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$42.33M$56.09M−24.5%
Cost of Revenue$1.09M$258K+324.3%
Gross Profit$41.23M$55.83M−26.1%
R&D Expenses$70.04M$57.56M+21.7%
SG&A Expenses$24.81M$18.10M+37.1%
Operating Expenses$95.95M$75.93M+26.4%
Operating Income-$53.63M-$19.84M−170.3%
Interest Expense$0$0—
Net Income-$53.55M-$19.77M−170.9%
EPS (Basic)$-0.48$-0.19−152.6%
Shares Outstanding (Basic)111.08M102.57M+8.3%

Frequently Asked Questions

  1. Why did the net loss increase in 2012 even though revenue was still substantial?

    Total revenues fell to $42.3 million from $56.1 million, while operating expenses rose to $95.9 million from $75.9 million. Research and development expense increased to $70.0 million from $57.6 million, mainly due to an $11.8 million increase in manufacturing activities and a $5.3 million increase in research activities, partly offset by a $5.2 million decrease in clinical trial activities. Selling, general and administrative expense rose to $24.8 million from $18.1 million as the commercial organization was built for the Hylenex recombinant reintroduction. The 2011 revenue also included $18.0 million from ViroPharma and Intrexon upfront payments and $18.1 million from the termination of the Baxter Hylenex collaboration, which did not recur at the same level in 2012.

  2. How much cash does Halozyme have and how long will it last?

    Cash and cash equivalents were $99.9 million at December 31, 2012. Management anticipates total net cash burn of approximately $45 to $50 million for 2013 and believes current cash is sufficient to fund operations for at least the next twelve months. It does not expect revenues to be sufficient to fund operations until 2014 at the earliest, and it may need additional financing through public offerings, new or revised collaborations, private financings or other equity or debt transactions.

  3. What is the risk from the FDA action involving rHuPH20?

    The FDA issued a complete response letter on August 1, 2012 for Baxter's HyQ BLA and asked for additional preclinical data on non-neutralizing antibodies to rHuPH20, and it requested that patients no longer be dosed with rHuPH20 in the Baxter HyQ program pending that data. ViroPharma's Cinryze study was placed on temporary hold and later allowed to resume. Halozyme does not believe the issues will significantly affect its proprietary and other collaboration candidates, but it notes that concerns could be raised by the FDA or other health authorities in the future, and most of its current products and candidates rely on rHuPH20.

  4. What did the Pfizer collaboration add in 2012?

    In December 2012 Halozyme and Pfizer entered into a collaboration and license agreement giving Pfizer a worldwide license to develop and commercialize products combining rHuPH20 with Pfizer proprietary biologics for up to six targets. Pfizer has elected three exclusive therapeutic targets in primary care and specialty care indications. Halozyme recognized $9.5 million of revenue in 2012 from the license fees, and Pfizer accounted for 22% of 2012 total revenues. Pfizer may terminate the agreement for any reason on 30 days' prior written notice.

  5. What new debt did Halozyme take on?

    In December 2012 Halozyme and its subsidiary Halozyme, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank for a $30 million secured single-draw term loan maturing January 1, 2017. The loan bears a fixed interest rate of 7.55% per annum, and the company received net proceeds of $29.7 million. The loan is secured by substantially all assets except intellectual property and certain excluded assets. The filing notes that a material adverse change is an event of default, which could accelerate repayment if it occurred.